tbuckley/cabot-search huggingface dataset:
VIRAL STIMULONS
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ROLE OF RENAL SCINTIGRAPHY IN THE EVALUATION OF IMPACT OF DONOR AGE ON RENAL TRANSPLANT RECIPIENTS
Authors: S. Dadparvar, F. Samimi, None Meihofar, Moy L. Krishna, J. A. Damaker, W. J. Slizofski, S. J. Brown, R. A. Roman, A. S. Khan
Journal: Clinical Nuclear Medicine (1993)

Dadparvar, S.; Samimi, F. M.A.; Meihofar, M.L.; Krishna, Moy L.; Damaker, J. A.; Slizofski, W. J.; Brown, S. J.; Roman, R. A.; Khan, A. S. Author Information
MEDICINE AT WAR IN SOUTH VIETNAM
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3461: Characterizing the PTEN - p85alpha interaction
Authors: Jeremy Marshall, Paul Mellor, Xuan Ruan, Dielle Whitecross, Stanley Moore, Deborah Anderson
Journal: Cancer Research (2019)

Abstract Introduction: The phosphatidylinositol 3-kinase (PI3K) pathway plays a key role in regulating cell growth and cell survival and is frequently deregulated in cancer cells. p85α regulates the p110α lipid kinase, and also stabilizes and stimulates PTEN, the lipid phosphatase that downregulates this pathway. We set out to identify residues in both PTEN and p85α that mediate their interaction to better understand the regions important in mediating binding. Experimental Procedures: We previously showed that the BH domain of p85α is sufficient to mediate binding to PTEN. In this work, a deletion analysis and point mutations were used to mutate each of PTEN and the p85α BH domain to identify residues important for binding, determined using a pull-down analysis. Mutations in the p85α BH domain and in PTEN that reduced their interaction were then used as input data and docking software was used to model possible interaction interfaces for the two the proteins. Further mutagenesis and follow-up binding experiments provided support for our model of the PTEN - p85α BH domain complex. Results: We identified key residues responsible for mediating PTEN - p85α complex formation. Based on these experimental results, a docking model for the PTEN - p85α BH domain complex was developed that is consistent with the known binding interactions for both PTEN and p85α. This model involves extensive side-chain and peptide backbone contacts between both the PASE (R84, Q87, Y88, E91, E99) and C2 (R189, P190, Q219, C250, D252) domains of PTEN and the p85α BH domains with a buried surface area of 1211 Å2 (PTEN - bovine p85α BH) and 1366 Å2 (PTEN - human p85α BH). The p85α BH domain residues that directly contact PTEN in the two docking models were not identical, however both models implicated p85α residues E212, Q221, K225, R228, H234 and W237. The majority of these p85α BH domain residues were confirmed experimentally as important for PTEN binding. We also verified experimentally the importance of PTEN-E91 in mediating interaction with the p85α BH domain. Conclusions: These results shed new light on the mechanism of PTEN binding and regulation by p85α. Citation Format: Jeremy Marshall, Paul Mellor, Xuan Ruan, Dielle Whitecross, Stanley Moore, Deborah Anderson. Characterizing the PTEN - p85alpha interaction [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3461.
Queries and Minor Notes.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antibiotic treatment for exacerbations of chronic obstructive pulmonary disease
Authors: E. A. Gilkey
Journal: JAMA (1995)

<h3>To the Editor.</h3> —Dr Saint and colleagues<sup>1</sup>have written an article in support of treating exacerbations of chronic obstructive pulmonary disease (COPD) with antibiotics. It is always nice to know one's applied standard of care is supported by the medical literature. Critical analysis revealed an exhaustive project leading to a conclusion with severe limitations. The selection criteria produced nine of 239 studies for metaanalysis. Randomized studies comparing treatment groups (antibiotics) vs control groups (placebo) were analyzed. A variety of outcomes were compared and averaged. In essence, averaged apples were compared with averaged oranges. No range of outcomes results were defined. For comparison between studies of effect size to be useful, the outcomes of a given study all must fall within a narrow range, with the mean defined as a representative sample of the population of outcomes studied. Even then, the mean of the means is suspect when the result
WASHINGTON NEWS
Journal: JAMA (1964)

<h3>Government Studies Tobacco Program.—</h3> US Surgeon General Luther Terry has ordered the Public Health Service to start work immediately on "appropriate remedial action" as a result of the findings of the Surgeon General's Advisory Committee that cigaret smoking is a health hazard. Terry indicated the major efforts would center around education campaigns aimed at the public and at stepped-up research into smoking's effect on health. He estimated the government is now spending several million dollars a year on research in this field. The American Medical Association's recentlyannounced long-range program of basic research on smoking is "meritorious," the Surgeon General told a news conference on the advisory committee's report. He said he did not believe the report should hamper future research in any way, and added that the AMA's program should increase over-all research. Edward R. Annis, MD, president of the AMA made the following comment on the report of the
Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections
Authors: A. P. Liang
Journal: JAMA (1983)

Animal studies have yielded conflicting results on the carcinogenicity of long-acting progestins. Since more than 1.5 million women worldwide are currently receiving injections of a contraceptive progestin, depot medroxyprogesterone acetate, this is potentially an important public health problem. We obtained information on the occurrence of breast, uterine, and ovarian cancer among 5,000 black women attending a metropolitan hospital's family planning clinic who had received injections of medroxyprogesterone for contraception (between 1967 and 1976). The women were followed up for four to 13 years after their initial medroxyprogesterone injection. We compared the observed number of cancer cases in these women with the expected number based on annual age-, race-, and sex-specific rates derived from National Cancer Institute data. During more than 40,000 woman-years of observation, we found no evidence of an increased risk of developing cancer of the breast, uterine corpus, or ovary in these women. After adjusting for possible underascertainment of cancer because of incomplete follow-up, we found the relative risk for medroxyprogesterone users to be 0.7 for breast cancer (95% confidence limits, 0.3 to 1.4), 1.2 (95% confidence limits, 0.1 to 6.7) for cancer of the uterine corpus, and 0.8 (95% confidence limits, 0.1 to 4.6) for ovarian cancer. (<i>JAMA</i>1983;249:2909-2912)
JOHN SCOTT HALDANE (1860-1936) RESPIRATION PHYSIOLOGIST
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Percy Jewsbury
Authors: M E Jewsbury
Journal: BMJ (2009)

A study is described in which three general practices were provided with low cost, low technology support from a "facilitator" and were compared with control practices in the ascertainment of major risk factors for cardiovascular disease in middle aged patients. Patients who were attending for a consultation with their general practitioners were recruited to make an appointment with a practice nurse for a health check, and this was compared with ordinary consultations in the control practices. Practices were helped by the facilitator to develop the nurse9s role. During the study the increase between intervention and control practices in blood pressure recording was doubled and in the recording of smoking habit it was quadrupled, and there was a fivefold increase in the recording of weight. This model can be applied to other aspects of prevention and general practice care.
Anesthesiology
Authors: Franklin B. McKechnie
Journal: JAMA (1987)

The specialty of anesthesiology continues to exhibit great activity in education, research, and expanding clinical practice roles. I have chosen to discuss three areas that are of interest at the present time: outpatient surgery, monitoring,and chronic pain control. As diagnosis related groups have put great pressure on hospitals to keep the census low, as surgeons have learned that it is not always necessary to keep patients in a hospital for three or four days postoperatively, and with the greater acceptance (and often desire) of patients to spend as little time in the hospital as possible, the demand and use of short-stay, outpatient facilities have grown rapidly. At present, these facilities take care of nearly 50% of the patients operated on each day in an acute-care hospital. Although the surgery remains the same whether the patient is in the hospital or is an outpatient, differences in anesthetic techniques are necessary for
The Marching Years.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical and Morphological Study of 256 Cases of Tumors of the Peripheral Nervous System
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rubella Among Crew Members of Commercial Cruise Ships—Florida, 1997
Journal: JAMA (1998)

During April-July 1997, two different commercial cruise lines notified CDC of rubella outbreaks among crew members. In July 1997, CDC initiated an investigation on one cruise ship to determine the extent of and risk factors for rubella infection among crew members and to assess the potential risk for rubella transmission to passengers-particularly rubella-susceptible pregnant women at risk for giving birth to an infant with congenital rubella syndrome (CRS). This report summarizes rubella outbreaks involving two cruise ships and the results of the CDC investigation on one cruise ship, which demonstrate that crew members can serve as a susceptible population for rubella infection and should be vaccinated with measles-mumps-rubella vaccine (MMR) if they are not immune. Although the outbreaks were limited to crew members, cruise ship travel provides an environment conducive to the potential spread of rubella and other infectious diseases among crew and passengers; therefore, women of childbearing age, particularly pregnant women, should be immune to rubella before traveling on cruise ships to reduce the risks for rubella infection and CRS.
Wilderness Medicine
Authors: Ian D. Jones, Nicole Streiff McCoin, Corey M. Slovis
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recommendations
Journal: Endoscopy (2011)

Reading committee: T Barrioz, A Barkun, R Laugier and JP Arpurt, T Barrioz, M Barthet, C Boustiere, P Burtin, A Calazel, JM Canard, C Cellier, B Croguennec, PA Dalbies, R Laugier, JC Letard, B Marchetti, P Pienkowski, F Prat, B Richard-Molard, JC Saurin of the SFED
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity
Authors: Douglas Osei-Hyiaman, Michael DePetrillo, Pál Pacher, Jie Liu, Svetlana Radaeva, Sándor Bátkai, Judith Harvey-White, Ken Mackie, László Offertáler, Lei Wang, George Kunos
Journal: Journal of Clinical Investigation (2005)

Endogenous cannabinoids acting at CB1 receptors stimulate appetite, and CB1 antagonists show promise in the treatment of obesity. CB1–/– mice are resistant to diet-induced obesity even though their caloric intake is similar to that of wild-type mice, suggesting that endocannabinoids also regulate fat metabolism. Here, we investigated the possible role of endocannabinoids in the regulation of hepatic lipogenesis. Activation of CB1 in mice increases the hepatic gene expression of the lipogenic transcription factor SREBP-1c and its targets acetyl-CoA carboxylase-1 and fatty acid synthase (FAS). Treatment with a CB1 agonist also increases de novo fatty acid synthesis in the liver or in isolated hepatocytes, which express CB1. High-fat diet increases hepatic levels of the endocannabinoid anandamide (arachidonoyl ethanolamide), CB1 density, and basal rates of fatty acid synthesis, and the latter is reduced by CB1 blockade. In the hypothalamus, where FAS inhibitors elicit anorexia, SREBP-1c and FAS expression are similarly affected by CB1 ligands. We conclude that anandamide acting at hepatic CB1 contributes to diet-induced obesity and that the FAS pathway may be a common molecular target for central appetitive and peripheral metabolic regulation.
Transactions of the Chicago Pathological Society, from October 1894, to November 1895.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New AIDS spread, old issues surface
Authors: P. Cotton
Journal: JAMA (1994)

NO ONE is expecting a breakthrough at the Tenth International Conference on AIDS this week in Yokohama, Japan. In fact, much attention there may be on issues that many have thought were settled, such as the increasingly doubtful value of surrogate markers for disease progression and drug efficacy. The recent screeching halt in US plans for large-scale vaccine efficacy trials after disappointing preliminary results also promises lively debate (see also pp 488-489). The conference itself is smaller this year, with about one third fewer abstracts accepted for oral and poster sessions than at last year's conference in Berlin, Germany. However, late submissions were being accepted and several late-breaker sessions are scheduled. "The goal of the organizers is to have as much up-to-date information as possible," says David Corkery of the conference's media liaison office for North America. Attendance may also be down, with many who have attended in previous years